Targeting Lymphatic Vessels for Ligand Directed Imaging

靶向淋巴管进行配体定向成像

基本信息

  • 批准号:
    9234681
  • 负责人:
  • 金额:
    $ 34.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-12-01 至 2021-11-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT . In particular, the The phenomenon of molecular changes to the lymphatic endothelial cells and the biological role(s) of the lymphatic vasculature in the metastatic cascade of human cancer are not entirely understood syndrome of in-transit melanoma is a fascinating clinical example of disease presentation in search of a pathophysiological basis. In our recent paper, Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis (Christianson et al. PNAS, 2015), we performed ex vivo combinatorial screens using random peptide phage libraries of draining lymphatic channels removed directly from patients during melanoma excision surgeries. We discovered a functional ligand-receptor system by selecting, isolating, and validating a new homophilic protein-protein interaction between malignant melanoma cells and lymphatic endothelial cells. This unique and previously unrecognized finding provides the foundation for the development and optimization of a new platform for ligand-directed imaging of the lymphatic system. Here, we propose to interrogate previously identified peptide ligands that bind to the surface of the lymphatic endothelium during disease progression to develop a novel, ligand-directed, non-invasive in vivo lymphatic imaging platform. Specifically, our goals are to: (1) Use innovative chem- and bio-informatics data mining systems to define the ontology of enriched lymphatic vessel homing peptides, (2) Investigate the binding properties of selected peptide ligands and their corresponding receptors in vitro, and (3) Develop and implement targeted imaging systems to study the lymphatic endothelium. Peptides that home to PPP2R1A, a new powerful lymphatic marker, will be prioritized. Our long-term goal, subsequent to the completion of the work proposed here, is to discover new lymphatic biomarkers associated with disease progression and generate a panel of ligand-based imaging agents that specifically target the surface of the lymphatic endothelium for prognostic and diagnostic translational applications. We anticipate that the newly characterized lymphatic molecular addresses and validated, corresponding ligands and antibodies will be of great value for the development of targeted agents, establishing for the first time, a platform for non-invasive imaging of the lymphatic system, and, in the future, contribute to our understanding of the role by the lymphatic vasculature in human disease.
摘要 。尤其是, 淋巴管内皮细胞的分子变化现象及其生物学作用(S) 淋巴血管在人类癌症转移级联中的作用尚不完全清楚 过境黑色素瘤综合征是一个引人入胜的临床例子,疾病的表现寻找一个 病理生理学基础。在我们最近的论文中,配体定向的淋巴管靶向揭示了 对黑色素瘤转移的机械论见解(Christian等人)。PNAS,2015),我们进行了体外实验 用随机肽噬菌体文库筛选直接去除引流淋巴道的组合 来自黑色素瘤切除手术的患者。我们发现了一个功能性的配体-受体系统,通过 恶性黑色素瘤间一种新的同嗜性蛋白-蛋白相互作用的筛选、分离和验证 细胞和淋巴管内皮细胞。这一独特的、以前未被承认的发现提供了基础 用于开发和优化一种新的配体导向淋巴系统成像平台。 在这里,我们建议询问先前发现的与淋巴管表面结合的多肽配体。 疾病进展过程中的内皮细胞发展一种新的、配体导向的、非侵入性体内淋巴管 成像平台。具体地说,我们的目标是:(1)使用创新的化学和生物信息学数据挖掘 系统定义丰富的淋巴管归巢多肽的本体,(2)研究结合 选定的多肽配体及其相应受体的体外性质,以及(3)开发和 实施靶向成像系统以研究淋巴管内皮细胞。PPP2R1A,a的故乡多肽 新的强大的淋巴标志物,将被优先考虑。我们的长期目标是,在完成 这里提出的工作是发现与疾病进展和疾病进展相关的新淋巴生物标志物 产生一组基于配体的显像剂,这些显像剂专门针对淋巴管表面 血管内皮细胞用于预测和诊断的翻译应用。我们预计,新的特征是 淋巴分子地址和经过验证的相应配体和抗体将对 靶向药物的开发,首次建立了无创成像的平台 淋巴系统,并在未来有助于我们理解淋巴血管系统在 人类疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WADIH ARAP其他文献

WADIH ARAP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WADIH ARAP', 18)}}的其他基金

Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10335200
  • 财政年份:
    2020
  • 资助金额:
    $ 34.66万
  • 项目类别:
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10553662
  • 财政年份:
    2020
  • 资助金额:
    $ 34.66万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10464889
  • 财政年份:
    2018
  • 资助金额:
    $ 34.66万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    9982236
  • 财政年份:
    2018
  • 资助金额:
    $ 34.66万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10202502
  • 财政年份:
    2018
  • 资助金额:
    $ 34.66万
  • 项目类别:
Targeting Lymphatic Vessels for Ligand Directed Imaging
靶向淋巴管进行配体定向成像
  • 批准号:
    10049234
  • 财政年份:
    2016
  • 资助金额:
    $ 34.66万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8669059
  • 财政年份:
    2013
  • 资助金额:
    $ 34.66万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8756663
  • 财政年份:
    2013
  • 资助金额:
    $ 34.66万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8271279
  • 财政年份:
    2010
  • 资助金额:
    $ 34.66万
  • 项目类别:
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis
检测侵袭性霉菌曲霉病的新临床诊断目标
  • 批准号:
    7945172
  • 财政年份:
    2010
  • 资助金额:
    $ 34.66万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 34.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了